2110122581
Search for:
Αρχική
Η Εταιρεία
Διοικητικό Συμβούλιο
Βιογραφικά
Νέα-Ανακοινώσεις
Δημοσιεύσεις
Ομιλίες
Επιστημονικό Υλικό
Online Εγγραφή
Επικοινωνία
Αρχική
Η Εταιρεία
Διοικητικό Συμβούλιο
Βιογραφικά
Νέα-Ανακοινώσεις
Δημοσιεύσεις
Ομιλίες
Επιστημονικό Υλικό
Online Εγγραφή
Επικοινωνία
Δημοσιεύσεις
2009 Guidelines
Αναθεωρημένες Κατευθυντήριες Οδηγίες της Ευρωπαϊκής Εταιρείας Υπέρτασης
2007 Guidelines
Introduction and purposes
Πίνακας Περιεχομένων
Υπέρταση Οδηγίες
Controversies in hypertension
ESH/ESC Guidelines: Definitions and Classification of BP Levels (mmHg)
Μελέτες
ACTION
Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo
Blood Pressure Reduction Is Not the Only Determinantof Outcome
CAMELOT: Study Design
CHARM
Clinical Significance of an Exaggerated Blood Pressure Response During Exercise
How to design and interpret controlled clinical trials
INternational VErapamil SR and Trandolapril STudy
Is New-Onset Diabetes of Clinical Significance in Treated Hypertensive Patients?—Con
More Confusing Messages From the Hypertension Treatment Trials
Φάρμακα
Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR–Modulating Activity
PPARγ Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin
Should blockers remain first choice in the treatment of primary hypertension? A meta-analysis
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension
Telmisartan in patients with mild/moderate hypertension and chronic kidney disease
The angiotensin II receptor antagonist telmisartan reduces rinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Μεταβολικό Σύνδρομο
Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor- Activity
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system
Comparison of the Effects of Ramipril Versus Telmisartan in Reducing Serum Levels of High-Sensitivity C-Reactive Protein and Oxidized Low-Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes Mellitus
Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ
Insulin-Sensitizing Effects of Telmisartan
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study Daily Life Blood Pressure, Cardiac Damage, and Prognosis
New Treatment Strategies for Patients with Hypertension and Insulin Resistance
PPAR Ligands: Potential Therapies for Metabolic Syndrome
The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects
Όργανα Στόχοι
Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy
How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis
Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers
Στεφ. Νόσος-Καρδιακή Ανεπάρκεια
“Polypill” to fight cardiovascular disease
“Polypill” to fight cardiovascular disease
“Polypill” for Cardiovascular Disease Prevention
A “Poly-Portfolio” for Secondary Prevention: A Strategy to Reduce Subsequent Events By Up to 97% Over Five Years
A cure for cardiovascular disease?
A strategy to reduce cardiovascular disease by more than 80%
Peroxisome proliferator-activated receptor-g agonists in atherosclerosis: current evidence and future directions
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
Relevance of blood pressure variation in the circadian onset of cardiovascular events
Take forward the polypill idea, concludes expert committee
Διάφορα
Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein Selective Modulator
Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisarta in patients with congestive heart failure
Exercise Capacity and 24-h Blood Pressure in Prehypertensive Men and Women
Exercise Capacity and Blood Pressure Associations With Left Ventricular Mass in Prehypertensive Individuals
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study
Telmisartan Plus HCTZ vs. Amlodipine Plus HCTZ in Older Patients With Systolic Hypertension: Results From a Large Ambulatory Blood Pressure Monitoring Study
The ASCOT trial: a closer look
The Year in Hypertension Bryan Williams, MD, FRCP, FAHA Leicester, United Kingdom
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
